Sr Manager, Medical Writing

Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company developing cell therapies for patients suffering from autoimmune diseases. Guided by our core values, Stay True to Why, Collaborate to Accelerate, Lead with Clarity, Boldly Innovative, and Own the Outcome, we are committed to transforming the future of treatment for autoimmune disease. Join us at the forefront of cell therapy innovation and help redefine what’s possible.

Title: Sr Manager, Medical Writing

Reports to: Sr. Director, Medical Writing
Location: Remote, United States (West coast hours preferred)

• Advanced degree (PhD, PharmD, MD, MS, or equivalent) in Life Sciences, Pharmacy, Medicine, or a related scientific discipline preferred.
• 10+ years of medical writing experience within the biotechnology or pharmaceutical industry.
• Extensive experience independently authoring FDA regulatory documents, including briefing packages, meeting requests, and clinical development documents.
• Proven experience developing FDA briefing documents supporting RMAT, Breakthrough Therapy Designation, or similar regulatory interactions.
• Strong experience writing clinical protocols and protocol synopses.
• Thorough understanding of FDA regulations, ICH guidelines, and GCP requirements.
• Ability to independently manage multiple projects with minimal supervision while meeting aggressive timelines.
• Exceptional scientific writing, editing, communication, and project management skills.
• Experience working in fast-paced, cross-functional clinical development environments.

The national salary range for this position is $170K to $190K USD annually.  The salary range is an estimate of what we reasonably expect to pay for this position, and the actual salary may vary based on various factors, including without limitation individual education, experience, tenure, skills and abilities, as well as internal equity and alignment with market data.  This position is also eligible for bonus, benefits, and participation in Company’s stock plan.